TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
-9.4%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.21B
AUM Growth
-$432M
(-16%)
Cap. Flow
-$82.9M
Cap. Flow
% of AUM
-3.75%
Top 10 Holdings %
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10
Top Buys
| 1 |
Biogen
BIIB
|
$15.1M |
| 2 |
Centene
CNC
|
$8.24M |
| 3 |
Moderna
MRNA
|
$7.61M |
| 4 |
Eli Lilly
LLY
|
$6.73M |
| 5 |
Sanofi
SNY
|
$6.15M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$14.8M |
| 2 |
Merck
MRK
|
$14.5M |
| 3 |
MDCO
Medicines Co
MDCO
|
$10.3M |
| 4 |
Johnson & Johnson
JNJ
|
$10.2M |
| 5 |
Pfizer
PFE
|
$8.65M |
Sector Composition
| 1 | Healthcare | 95.66% |
| 2 | Real Estate | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
51
DELISTED
Blueprint Medicines
BPMC
| $8.15M | 0.37% |
139,336
+22,411
| +19% | +$1.31M |
|
52
Omega Healthcare
OHI
$12.7B
| $8.13M | 0.37% |
306,433
+21,638
| +8% | +$574K |
|
53
Novo Nordisk
NVO
$245B
| $8.07M | 0.36% |
268,010
-174,718
| -39% | -$5.26M |
|
54
McKesson
MCK
$85.5B
| $8.05M | 0.36% |
59,525
-7,800
| -12% | -$1.05M |
|
55
Zimmer Biomet
ZBH
$20.9B
| $7.9M | 0.36% |
80,513
+14,932
| +23% | +$1.47M |
|
56
Baxter International
BAX
$12.5B
| $7.89M | 0.36% |
97,183
-32,800
| -25% | -$2.66M |
|
57
GSK
GSK
$81.5B
| $7.84M | 0.35% |
165,494
-40,144
| -20% | -$1.9M |
|
58
Ascendis Pharma
ASND
$12.5B
| $7.81M | 0.35% |
69,332
| – | – |
|
|
59
Moderna
MRNA
$9.78B
| $7.61M | 0.34% |
+254,146
| New | +$7.61M |
|
60
HCA Healthcare
HCA
$98.5B
| $7.53M | 0.34% |
83,833
-12,000
| -13% | -$1.08M |
|
61
NovoCure
NVCR
$1.37B
| $7.24M | 0.33% |
107,438
| – | – |
|
62
Medical Properties Trust
MPW
$2.77B
| $7.12M | 0.32% |
411,743
+37,454
| +10% | +$648K |
|
63
Teva Pharmaceuticals
TEVA
$21.7B
| $7.06M | 0.32% |
785,851
| – | – |
|
|
DOC
64
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $6.91M | 0.31% |
495,733
+38,977
| +9% | +$543K |
|
65
FibroGen
FGEN
$48.9M
| $6.75M | 0.31% |
7,771
| – | – |
|
66
Jazz Pharmaceuticals
JAZZ
$7.86B
| $6.73M | 0.3% |
67,456
-18,217
| -21% | -$1.82M |
|
67
Agios Pharmaceuticals
AGIO
$2.09B
| $6.63M | 0.3% |
186,964
-29,444
| -14% | -$1.04M |
|
68
Iovance Biotherapeutics
IOVA
$901M
| $6.62M | 0.3% |
221,073
-22,410
| -9% | -$671K |
|
|
IMMU
69
DELISTED
Immunomedics Inc
IMMU
| $6.57M | 0.3% |
487,103
| – | – |
|
70
Sutro Biopharma
STRO
$89.9M
| $6.54M | 0.3% |
641,268
| – | – |
|
|
MRTX
71
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.06M | 0.27% |
78,784
+7,911
| +11% | +$608K |
|
|
GBT
72
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $6.03M | 0.27% |
118,083
-29,085
| -20% | -$1.49M |
|
73
United Therapeutics
UTHR
$18.1B
| $6.02M | 0.27% |
63,513
+9,419
| +17% | +$893K |
|
74
argenx
ARGX
$45.9B
| $5.93M | 0.27% |
44,977
| – | – |
|
|
BCEL
75
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $5.83M | 0.26% |
352,424
-172,472
| -33% | -$2.85M |
|